Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Refractory Solid Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT02508441
What this trial is testing

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

Who this might be right for
Advanced Unresectable Solid Tumors
Andes Biotechnologies 22
Early research (Phase 1)Active Not RecruitingNCT04503278
What this trial is testing

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

Who this might be right for
Solid Tumor
BioNTech Cell & Gene Therapies GmbH 214
Early research (Phase 1)Ended earlyNCT03861403
What this trial is testing

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer+2 more
Leap Therapeutics, Inc. 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03698994
What this trial is testing

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Ependymal TumorRecurrent Ewing Sarcoma+33 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT02535312
What this trial is testing

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Who this might be right for
Advanced Malignant Solid NeoplasmAdvanced Peritoneal Malignant MesotheliomaAdvanced Pleural Malignant Mesothelioma+4 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT04306224
What this trial is testing

IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Who this might be right for
Solid TumorLymphoma
ImmuneOncia Therapeutics Inc. 12
Early research (Phase 1)Study completedNCT01209143
What this trial is testing

Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Who this might be right for
Solid Cancers
Genentech, Inc. 52
Early research (Phase 1)Study completedNCT00608361
What this trial is testing

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Who this might be right for
Adult Acute Lymphoblastic Leukemia in RemissionAdult B Acute Lymphoblastic LeukemiaAdult Hepatocellular Carcinoma+82 more
National Cancer Institute (NCI) 80
Early research (Phase 1)Study completedNCT00816361
What this trial is testing

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Who this might be right for
Cancer
MedImmune LLC 43
Early research (Phase 1)Study completedNCT00816400
What this trial is testing

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Who this might be right for
Cancer
MedImmune LLC 49
Early research (Phase 1)Ended earlyNCT03065387
What this trial is testing

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Who this might be right for
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene Mutation+7 more
M.D. Anderson Cancer Center 84
Early research (Phase 1)Ended earlyNCT02110563
What this trial is testing

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Who this might be right for
Solid TumorsMultiple MyelomaNon-Hodgkins Lymphoma+3 more
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 50
Early research (Phase 1)Study completedNCT04742556
What this trial is testing

Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT03210714
What this trial is testing

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell Tumor+29 more
National Cancer Institute (NCI) 20
Early research (Phase 1)Study completedNCT00003004
What this trial is testing

Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Memorial Sloan Kettering Cancer Center 73
Early research (Phase 1)Study completedNCT03430882
What this trial is testing

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Who this might be right for
Recurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
M.D. Anderson Cancer Center 35
Early research (Phase 1)Study completedNCT01976741
What this trial is testing

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Who this might be right for
Neoplasms
Bayer 168
Testing effectiveness (Phase 2)Ended earlyNCT03323398
What this trial is testing

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Who this might be right for
Relapsed/Refractory Solid Tumor Malignancies or LymphomaOvarian Cancer
ModernaTX, Inc. 79
Early research (Phase 1)Study completedNCT00060632
What this trial is testing

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Who this might be right for
TumorsLymphomaMultiple Myeloma
Merck Sharp & Dohme LLC 46
Early research (Phase 1)Ended earlyNCT04553692
What this trial is testing

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Who this might be right for
Solid TumorColorectal CancerNon Hodgkin Lymphoma+5 more
IGM Biosciences, Inc. 272
Next Page
30